What 2025 revealed about cybersecurity in high-risk industries, from failing assumptions and credential exposure to cloud misconfigurations and GenAI risk.

AI is transforming how biotech and longevity companies interpret biomarkers, blood panels, and genomics — but the moment your AI starts informing diagnosis or clinical decisions, it becomes a regulated medical device. This guide breaks down the regulatory line, FDA/MDR implications, PCCP, cybersecurity requirements, and how to build compliant AI systems without slowing innovation.

Generative AI is transforming biotechnology — from drug discovery to genomics — but it is also creating a new class of cyberbiosecurity risks. As biological data, AI models, and laboratory systems converge, the attack surface expands beyond databases to the algorithms designing the next generation of medicine.